{
    "abstract": "Women with obesity and/or type-II-diabetes have an increased breast cancer risk, increased metastasis, and poorer prognosis, especially after menopause. In a rat model of high-fat-diet and menopause-induced weight gain, we previously reported that treatment with the anti-diabetic drug metformin for 8-weeks after ovariectomy (OVX; modeling menopause) reduced growth of existing mammary tumors and inhibited new tumor formation. This identified the menopause transition as a potential window-of-opportunity for interventions to decrease obesity-associated breast cancer incidence and disease progression. Here, we extend these findings to determine if limiting metformin to the peak window of OVX-induced weight gain would have similar anti-cancer effects.\nMetformin during the first four weeks following OVX is critical to reducing tumor burden, as rats treated with metformin early (weeks0-4-postOVX) had reduced tumor burden. Conversely, initiating metformin later in the postOVX period (weeks 4-8postOVX) did not reduce cancer burden. Despite improved tumor outcomes, metformin withdrawal after the early postOVX time had detrimental metabolic effects, including weight gain and increased adiposity, insulin, IGF1, and HOMA-IR, which correlate with increased cancer risk.\nThese data reveal early-postmenopause as a critical window when metformin decreases progression of existing disease and highlights the importance of maintaining treatment to prevent metabolic dysregulation, which could promote secondary tumors/metastasis. These findings also help explain the disconnect between epidemiological studies reporting anticancer benefits of metformin and more recent clinical trials that failed to see similar efficacy, potentially due to issues of timing and/or inclusion of women outside the early postmenopausal window and/or without underlying metabolic dysfunction.",
    "authors": [
        {
            "affiliation": null,
            "firstname": "Karen A",
            "initials": "KA",
            "lastname": "Corleto"
        },
        {
            "affiliation": null,
            "firstname": "Pepper",
            "initials": "P",
            "lastname": "Schedin"
        },
        {
            "affiliation": null,
            "firstname": "Anuhya S",
            "initials": "AS",
            "lastname": "Kotta"
        },
        {
            "affiliation": null,
            "firstname": "Jenna L",
            "initials": "JL",
            "lastname": "Strandmo"
        },
        {
            "affiliation": null,
            "firstname": "Samantha M",
            "initials": "SM",
            "lastname": "Foster"
        },
        {
            "affiliation": null,
            "firstname": "Nanci",
            "initials": "N",
            "lastname": "Lammoglia"
        },
        {
            "affiliation": null,
            "firstname": "Moumita",
            "initials": "M",
            "lastname": "Karmakar"
        },
        {
            "affiliation": null,
            "firstname": "Raymond J",
            "initials": "RJ",
            "lastname": "Carroll"
        },
        {
            "affiliation": null,
            "firstname": "Paul S",
            "initials": "PS",
            "lastname": "MacLean"
        },
        {
            "affiliation": null,
            "firstname": "Erin D",
            "initials": "ED",
            "lastname": "Giles"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.1101/2024.11.25.625083",
    "journal": "bioRxiv : the preprint server for biology",
    "keywords": [],
    "methods": null,
    "publication_date": "2024-12-09",
    "pubmed_id": "39651199",
    "results": null,
    "title": "Targeting the menopause transition with metformin improves breast cancer outcomes, but discontinuation has deleterious effects on metabolic health: Findings from a preclinical model of postmenopausal breast cancer.",
    "xml": "<Element 'PubmedArticle' at 0x788502e9b470>"
}